person · Reporting owner
Little Elisabeth Sandoval
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INCALDR · Entity 154258 | CCO & EVP, Corporate Strategy | February 16, 2018 | February 21, 2018 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | May 13, 2022 | May 16, 2022 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director | June 09, 2026 | June 10, 2026 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALDER BIOPHARMACEUTICALS INC
Report date February 16, 2018 · Filed February 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2028-02-15 | Direct | 60,000 |
Reported balance
After 2018-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.
Intersect ENT, Inc.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.98 · Expires 2031-04-04 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-13 · Other · Disposed 15,896 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
PROCEPT BioRobotics Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,876 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 15,876 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08 | Direct | 5,853 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Yarrow Bioscience, Inc.
Report date December 12, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2035-12-11 | Direct | 20,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Satsuma Pharmaceuticals, Inc.
Report date June 08, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.99 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-08 · Disposition to issuer · Disposed 14,893 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:41 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 5,853 | $0.00 Strike: $28.78 | $0.00 |
DisclosureSEC source: 0001628280-26-042263 · wk-form4_1781124060.xml · derivative · entry 2 Little Elisabeth Sandoval · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,853 Underlying: Common Stock · 5,853 shares Expires 2036-06-08 F2 · derivative.exercise_date: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 20:41 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 3,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042263 · wk-form4_1781124060.xml · nonDerivative · entry 1 Little Elisabeth Sandoval · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,876 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| December 12, 2025 Filed Dec 15, 2025 21:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001632295-25-000005 · form4-12152025_041207.xml · derivative · entry 1 Little Elisabeth Sandoval · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:26 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $64.23 | $0.00 |
DisclosureSEC source: 0001628280-25-030992 · wk-form4_1749759999.xml · derivative · entry 2 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,771 shares Expires 2035-06-09 F2 · derivative.exercise_date: The Stock option was granted on June 10, 2025 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:26 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 1,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030992 · wk-form4_1749759999.xml · nonDerivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,561 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-24-029287 · form4-12132024_041209.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:24 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 2,526 | $0.00 Strike: $67.29 | $0.00 |
DisclosureSEC source: 0001628280-24-027037 · wk-form4_1717705462.xml · derivative · entry 2 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,526 Underlying: Common Stock · 2,526 shares Expires 2034-06-03 F2 · derivative.exercise_date: The Stock Option was granted on June 4, 2024 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:24 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027037 · wk-form4_1717705462.xml · nonDerivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,023 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:14 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000463 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:06 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058813 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:48 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 4,865 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001628280-23-022495 · wk-form4_1686948472.xml · derivative · entry 2 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,865 Underlying: Common Stock · 4,865 shares Expires 2033-06-14 F2 · derivative.exercise_date: The Stock Option was granted on June 15, 2023 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:48 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 2,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022495 · wk-form4_1686948472.xml · nonDerivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,647 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:38 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 14,893 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0000899243-23-014886 · doc4.xml · derivative · entry 4 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,893 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:38 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0000899243-23-014886 · doc4.xml · derivative · entry 3 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:38 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0000899243-23-014886 · doc4.xml · derivative · entry 2 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:38 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0000899243-23-014886 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 21:12 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-22-045653 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-08-10 F1 · derivative.exercise_date: Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:13 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock · Derivative | 4,205 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0001628280-22-016687 · wf-form4_165480559749251.xml · derivative · entry 2 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,205 Underlying: Common Stock · 4,205 shares Expires 2032-06-06 F2 · price: The Stock option was granted on June 7, 2022 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. F2 · derivative.exercise_date: The Stock option was granted on June 7, 2022 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:13 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 2,001 | $37.48 | $74,997.48 |
DisclosureSEC source: 0001628280-22-016687 · wf-form4_165480559749251.xml · nonDerivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,936 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 17:37 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001567619-22-012475 · doc1.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting. Read SEC document |
| May 13, 2022 Filed May 16, 2022 18:39 UTC | Intersect ENT, Inc. XENT · Entity 127294 | OtherStock Options (Right to buy) · Derivative | 15,896 | $28.25 Strike: $20.98 | $449,062.00 |
DisclosureSEC source: 0001562180-22-004072 · primarydocument.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,896 shares Expires 2031-04-04 F1 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F1 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 23:31 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 4,935 | $40.46 | $199,670.10 |
DisclosureSEC source: 0001588978-21-000006 · wf-form4_163520465895133.xml · nonDerivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,935 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on October 21, 2022, with one-third of the remaining RSUs vesting annually on each anniversary thereof, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 21:06 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-047412 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2031-07-19 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 18:18 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 15,896 | $0.00 Strike: $20.98 | $0.00 |
DisclosureSEC source: 0001562180-21-002746 · primarydocument.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,896 Underlying: Common Stock · 15,896 shares Expires 2031-04-04 F1 · derivative.exercise_date: The vesting commencement date of the option is April 5, 2021. 1/4th of the shares subject to the option shall vest on April 5, 2022 and 1/48th of the shares subject to the option shall vest monthly thereafter over 36 months. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 18:04 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001567619-20-020720 · doc1.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-03 F1 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2022 Annual Meeting. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:39 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 22,500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-045131 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-08-03 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:25 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001567619-20-012251 · doc1.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 20:45 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-20-020663 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:15 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 11,645 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000899243-19-018352 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 11,645 shares Expires 2029-03-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of appointment to the Board, subject to Ms. Sandoval's continued service to the Company through each applicable vesting date. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:10 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 33,355 | $0.00 Strike: $8.24 | $0.00 |
DisclosureSEC source: 0000899243-19-008679 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,355 Underlying: Common Stock · 33,355 shares Expires 2029-03-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of appointment to the Board, subject to Ms. Sandoval's continued service to the Company through each applicable vesting date. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:42 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012047 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · CCO & EVP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 17:14 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001209191-17-066830 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-12-19 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 17:26 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-17-006431 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 18:09 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $31.47 | $0.00 |
DisclosureSEC source: 0001209191-16-145446 · doc4.xml · derivative · entry 1 Sandoval Elisabeth · CIK 0001632295 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2026-10-04 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of August 30, 2016 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.